Can Monthly Dosing Move BCMA Bispecifics Out of the Myeloma Center?
AbbVie's etentamig beat older salvage on response and progression-free survival in Phase 3 CERVINO. The harder question is whether a single step-up and monthly intravenous schedule can loosen the REMS-and-hospitalization architecture that still gates approved BCMA T-cell engagers.
AbbVie announced on September 3, 2026 that etentamig, an investigational BCMA x CD3 bispecific T-cell engager also known as ABBV-383, met both dual primary endpoints in Phase 3 CERVINO: overall response rate and progression-free survival. The win is against yesterday's salvage, not the BCMA T-cell engagers already in clinics.
The commercial question is access. Approved BCMA bispecifics sit under REMS programs and step-up hospitalization rules that concentrate care in specialized centers. AbbVie argues that a single step-up dose, then monthly intravenous dosing from initiation, has the potential to open outpatient and community settings. That remains a claim about potential, not a demonstrated practice pattern. Etentamig is not approved by global regulatory authorities.
Dual primaries, one unfinished survival question
At the first planned efficacy interim analysis, 393 patients had reached the data cutoff, with a median of three prior lines and 11.4 months of follow-up. An independent data monitoring committee recommended unblinding on the basis of significant benefit. ORR was 74.0% (95% CI 67.25-79.97) versus 45.7% (95% CI 38.59-52.91) on standard available therapies, P<0.0001. The PFS hazard ratio was 0.40 (95% CI 0.29-0.54), P<0.0001, a 60% reduction in the risk of disease progression or death, with benefit observed across all pre-specified subgroups evaluated.
Overall survival is unfinished. Twelve-month OS was 87.9% on etentamig versus 72.0% on SAT, HR 0.48 (95% CI 0.29-0.77), nominal P=0.0012. The prespecified efficacy boundary for OS was not crossed at the data cutoff. A nominal P value is not a crossed survival gate. Full results are scheduled for a September 25, 2026 plenary at the International Myeloma Society meeting in Glasgow. AbbVie plans to discuss the results with global regulators.
The control arm AbbVie actually beat
The open-label trial enrolled 421 patients, randomized 1:1, and remains ACTIVE_NOT_RECRUITING. Etentamig was given as intravenous monotherapy in 28-day cycles against investigator's choice among three older SAT regimens: carfilzomib plus dexamethasone (Kd); elotuzumab, pomalidomide, and dexamethasone (EloPd); or selinexor, bortezomib, and dexamethasone (SVd). Those are non-BCMA salvage options, not teclistamab, elranatamab, or a BCMA CAR-T.
Eligibility sharpens the limit. Patients had to be ECOG 2 or better and triple-class exposed to a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody. Prior BCMA-targeted therapy was excluded, as was CNS involvement of myeloma. In today's relapsed population, Tecvayli, Elrexfio, and BCMA CAR-T are already in use. CERVINO does not say what etentamig does after those drugs. Fierce Biotech has noted a crowded class that already includes Tecvayli, Elrexfio, and Abecma.
Why CRS grade is not the same as access
Among patients who received a single step-up dose, cytokine release syndrome occurred in 28.3% and was predominantly grade 1 (23.9%), with no grade 3 or higher CRS reported. ICANS was limited to one patient (0.9%, grade 1), with no grade 2 or higher events. Treatment-emergent adverse events leading to discontinuation were 3.6% on etentamig versus 9.6% on SAT. Peter Voorhees, a CERVINO investigator at Atrium Health Levine Cancer Institute, called the PFS and response gains clinically meaningful.
Those CRS figures cannot be stacked against approved labels as if they came from the same trial. Different studies and schedules are not comparable. What the labels establish is the access tax attached to the class. The Tecvayli FDA label reports CRS in 72% at the recommended dose and ICANS in 6%, requires hospitalization for 48 hours after all doses within the step-up schedule, and restricts the product to a TECVAYLI and TALVEY REMS. The Elrexfio label reports CRS in 58% and ICANS in 3.3%, also under an ELREXFIO REMS, with 48-hour hospitalization after the first step-up dose and 24 hours after the second. Those operational constraints, not a cross-trial CRS ranking, are the contrast AbbVie wants noticed.
Infections are the clearer trade-off inside CERVINO itself. Grade 3 or 4 infections were higher on etentamig, 27.7% versus 19.2% on SAT. Fatal (grade 5) infections ran the other way, 1.5% versus 3.1%. Any outpatient story has to carry both numbers. AbbVie describes a low-affinity CD3 domain designed to reduce CRS and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding that enables monthly dosing after a single step-up. Clinical correlations of that structure-activity story are not fully established. A 2022 Phase 1 study tested ABBV-383 every three weeks without step dosing, with CRS in 57% of 124 patients, mostly grade 1 or 2.
What regulators still have to weigh
CERVINO started May 19, 2024, with primary completion listed in December 2027, at 166 sites across 25 countries. Open-label design is a caveat on response assessment, even with IRC review. The efficacy population at cutoff (393) is not the full enrolled set (421). Survival remains immature. Prior BCMA therapy was written out of the study, and the control arm is older SAT. CERVINO puts a Phase 3 ORR and PFS win and a monthly schedule after one step-up on the table. It does not settle whether infection risk, REMS precedent, and a BCMA-naive trial population will keep etentamig in the same specialized funnel as drugs already on the market.